US FDA Emphasizes Risk Analysis, Labeling In Device Interoperability Draft Guidance
This article was originally published in SRA
Executive Summary
For medtech manufacturers designing medical devices intended to be interoperable with other systems, the US Food and Drug Administration has spelled out its premarket expectations for proper risk analyses, verification and validation studies, and labeling.